Breaking Down SG&A Expenses: Merck & Co., Inc. vs Taro Pharmaceutical Industries Ltd.

SG&A Expenses: Merck vs Taro - A Decade of Financial Insights

__timestampMerck & Co., Inc.Taro Pharmaceutical Industries Ltd.
Wednesday, January 1, 20141160600000091733000
Thursday, January 1, 20151031300000087644000
Friday, January 1, 2016976200000092365000
Sunday, January 1, 2017983000000085656000
Monday, January 1, 20181010200000088196000
Tuesday, January 1, 20191061500000089971000
Wednesday, January 1, 2020895500000093413000
Friday, January 1, 2021963400000091355000
Saturday, January 1, 202210042000000113676000
Sunday, January 1, 202310504000000198366000
Monday, January 1, 2024218935000
Loading chart...

Cracking the code

A Comparative Analysis of SG&A Expenses: Merck & Co., Inc. vs Taro Pharmaceutical Industries Ltd.

In the ever-evolving pharmaceutical industry, understanding the financial dynamics of major players is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of two prominent companies: Merck & Co., Inc. and Taro Pharmaceutical Industries Ltd., from 2014 to 2023.

Merck, a global leader, consistently reported SG&A expenses averaging around $10 billion annually, reflecting its expansive operations and marketing efforts. In contrast, Taro, a smaller entity, maintained a more modest average of approximately $113 million, highlighting its leaner structure. Notably, Taro's expenses surged by over 70% from 2022 to 2023, indicating potential strategic shifts or increased operational costs.

This financial juxtaposition underscores the diverse strategies within the pharmaceutical sector, where scale and market focus significantly influence expenditure patterns.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025